Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder
The lack of adequate treatment for many patients with opioid use disorder (OUD) has led to high medical costs ($90B in 2020). An analysis of the cost-effectiveness (cost-utility) of reSET-O, the first and only FDA-approved prescription digital therapeutic (PDT) for the treatment of OUD, is needed to...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2021.1966187 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849413707371642880 |
|---|---|
| author | Fulton F. Velez Daniel C. Malone |
| author_facet | Fulton F. Velez Daniel C. Malone |
| author_sort | Fulton F. Velez |
| collection | DOAJ |
| description | The lack of adequate treatment for many patients with opioid use disorder (OUD) has led to high medical costs ($90B in 2020). An analysis of the cost-effectiveness (cost-utility) of reSET-O, the first and only FDA-approved prescription digital therapeutic (PDT) for the treatment of OUD, is needed to inform value assessments and healthcare decision making. To evaluate the cost-utility of reSET-O in conjunction with treatment-as usual (TAU) compared to TAU alone. A third-party payer-perspective decision analytic model evaluated the cost-effectiveness of reSET-O + TAU relative to TAU (i.e., oral buprenorphine, face-to-face counseling, and contingency management [immediate rewards for negative drug tests logged]) alone over 12 weeks. Clinical effectiveness data (retention in therapy and health state utilities) were obtained from the peer-reviewed literature, while resource utilization and cost data were obtained from a published claims data analyses. Over 12 weeks, the addition of reSET-O to TAU resulted in a gain of 0.003 quality-adjusted life years (QALYs), and $1,014 lower costs, resulting in economic dominance vs. TAU. reSET-O + TAU’s was economically dominant (less costly, more effective) vs. TAU alone over 12 weeks, a result that was driven by a reduction in medical costs after initiation of reSET-O observed in a recent real-world claims analysis. |
| format | Article |
| id | doaj-art-67822499b65b4ffd963421fc70fcd299 |
| institution | Kabale University |
| issn | 2001-6689 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Market Access & Health Policy |
| spelling | doaj-art-67822499b65b4ffd963421fc70fcd2992025-08-20T03:34:02ZengMDPI AGJournal of Market Access & Health Policy2001-66892021-01-019110.1080/20016689.2021.19661871966187Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use DisorderFulton F. Velez0Daniel C. Malone1Pear Therapeutics, IncStrategic Therapeutics, LLCThe lack of adequate treatment for many patients with opioid use disorder (OUD) has led to high medical costs ($90B in 2020). An analysis of the cost-effectiveness (cost-utility) of reSET-O, the first and only FDA-approved prescription digital therapeutic (PDT) for the treatment of OUD, is needed to inform value assessments and healthcare decision making. To evaluate the cost-utility of reSET-O in conjunction with treatment-as usual (TAU) compared to TAU alone. A third-party payer-perspective decision analytic model evaluated the cost-effectiveness of reSET-O + TAU relative to TAU (i.e., oral buprenorphine, face-to-face counseling, and contingency management [immediate rewards for negative drug tests logged]) alone over 12 weeks. Clinical effectiveness data (retention in therapy and health state utilities) were obtained from the peer-reviewed literature, while resource utilization and cost data were obtained from a published claims data analyses. Over 12 weeks, the addition of reSET-O to TAU resulted in a gain of 0.003 quality-adjusted life years (QALYs), and $1,014 lower costs, resulting in economic dominance vs. TAU. reSET-O + TAU’s was economically dominant (less costly, more effective) vs. TAU alone over 12 weeks, a result that was driven by a reduction in medical costs after initiation of reSET-O observed in a recent real-world claims analysis.http://dx.doi.org/10.1080/20016689.2021.1966187cost-effectivenesscost-utility analysisreal-world evidenceopioid use disorderretention in therapyprescription digital therapeutics |
| spellingShingle | Fulton F. Velez Daniel C. Malone Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder Journal of Market Access & Health Policy cost-effectiveness cost-utility analysis real-world evidence opioid use disorder retention in therapy prescription digital therapeutics |
| title | Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder |
| title_full | Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder |
| title_fullStr | Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder |
| title_full_unstemmed | Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder |
| title_short | Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder |
| title_sort | cost effectiveness analysis of a prescription digital therapeutic for the treatment of opioid use disorder |
| topic | cost-effectiveness cost-utility analysis real-world evidence opioid use disorder retention in therapy prescription digital therapeutics |
| url | http://dx.doi.org/10.1080/20016689.2021.1966187 |
| work_keys_str_mv | AT fultonfvelez costeffectivenessanalysisofaprescriptiondigitaltherapeuticforthetreatmentofopioidusedisorder AT danielcmalone costeffectivenessanalysisofaprescriptiondigitaltherapeuticforthetreatmentofopioidusedisorder |